Zimmer Biomet Holdings Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 10/3/2026)
| Balance Sheet | Total Assets | 23,091,700,000.00 | ROE | 54.99 % |
| Balance Sheet | Total Equity | 12,705,800,000.00 | ROA | 3.05 % |
| Cashflow | Capital Expenditures | -224,500,000.00 | P/FCF | 12.38 |
| Cashflow | Free Cash Flow | 1,472,600,000.00 | – | – |
| Cashflow | Operating Cash Flow | 1,697,000,000.00 | P/CF | 10.74 |
| Income | Earnings per Share (diluted) | 3.55 | Div. Yield | 1.05 % |
| Income | Net Income | 705,100,000.00 | P/E | 25.85 |
| Income | Shares Outstanding | 198,700,000.00 | P/B | 1.44 |
| Income | Total Revenue | 8,231,500,000.00 | P/S | 2.22 |
Ratios calculated on: 10/14/2026
Company Description
As a leading innovator in musculoskeletal healthcare, we offer a complete portfolio of products for joint reconstruction, bone and skeletal repair, sports medicine, spine, and dental reconstruction. Every day, we focus on improving musculoskeletal healthcare. It's all we do. It's all we've ever done. For nearly 90 years, Zimmer Biomet has helped people progress beyond their pain and limitations. We serve healthcare professionals and their patients globally. At Zimmer Biomet, it's not just what we make, it's what we make possible.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.zimmer.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more